Cargando…

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

The receptor tyrosine kinase HER2 acts as oncogenic driver in numerous cancers. Usually, the gene is amplified, resulting in receptor overexpression, massively increased signaling and unchecked proliferation. However, tumors become frequently addicted to oncogenes and hence are druggable by targeted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kast, Florian, Schwill, Martin, Stüber, Jakob C., Pfundstein, Svende, Nagy-Davidescu, Gabriela, Rodríguez, Josep M. Monné, Seehusen, Frauke, Richter, Christian P., Honegger, Annemarie, Hartmann, Karen Patricia, Weber, Thomas G., Kroener, Felix, Ernst, Patrick, Piehler, Jacob, Plückthun, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213836/ https://www.ncbi.nlm.nih.gov/pubmed/34145240 http://dx.doi.org/10.1038/s41467-021-23948-6

Ejemplares similares

Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
por: Tamaskovic, Rastislav, et al.
Publicado: (2016)

Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization
por: Stüber, Jakob C., et al.
Publicado: (2021)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
por: Cheng, Jackie, et al.
Publicado: (2020)

A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation
por: Benedetti, Filippo, et al.
Publicado: (2021)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH
por: Emmerson, Chris D., et al.
Publicado: (2011)

Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4(+) Cancers
por: Cano-Garrido, Olivia, et al.
Publicado: (2021)

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
por: Liu, Jiayu, et al.
Publicado: (2019)

Rigid fusions of designed helical repeat binding proteins efficiently protect a binding surface from crystal contacts
por: Ernst, Patrick, et al.
Publicado: (2019)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging
por: Goldstein, Robert, et al.
Publicado: (2014)

The Deubiquitinase OTUB1 Is a Key Regulator of Energy Metabolism
por: Ruiz-Serrano, Amalia, et al.
Publicado: (2022)

A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
por: Shi, Sally Yu, et al.
Publicado: (2018)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance
por: Walter, Justin D, et al.
Publicado: (2022)

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
por: Pymm, Phillip, et al.
Publicado: (2022)

Rigidly connected multispecific artificial binders with adjustable geometries
por: Wu, Yufan, et al.
Publicado: (2017)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

Expeditious Generation of Biparatopic Common Light Chain Antibodies via Chicken Immunization and Yeast Display Screening
por: Bogen, Jan P., et al.
Publicado: (2020)

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
por: Wagner, Teresa R, et al.
Publicado: (2021)

Labeling surface proteins with high specificity: Intrinsic limitations of phosphopantetheinyl transferase systems
por: Stüber, Jakob C., et al.
Publicado: (2019)

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
por: Chen, Chuan, et al.
Publicado: (2022)

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
por: Ugamraj, Harshad S., et al.
Publicado: (2022)

Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2
por: Faria, Morse, et al.
Publicado: (2019)

In vivo Sealing of Fetoscopy-Induced Fetal Membrane Defects by Mussel Glue
por: Avilla-Royo, Eva, et al.
Publicado: (2023)

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model
por: Mitran, Bogdan, et al.
Publicado: (2018)

Generation of biparatopic antibody through two-step targeting of fragment antibodies on antigen using SpyTag and SpyCatcher
por: Akiba, Hiroki, et al.
Publicado: (2020)

A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms
por: Stefano, James E., et al.
Publicado: (2021)

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models
por: Fan, Jiansheng, et al.
Publicado: (2021)

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
por: DaSilva, John O., et al.
Publicado: (2021)

Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity
por: Fleetwood, Filippa, et al.
Publicado: (2014)

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
por: Godar, Marie, et al.
Publicado: (2016)

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018)

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
por: Miao, Xiaoniu, et al.
Publicado: (2020)

Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection
por: Akiba, Hiroki, et al.
Publicado: (2023)

Design and applications of a clamp for Green Fluorescent Protein with picomolar affinity
por: Hansen, Simon, et al.
Publicado: (2017)

Directed evolution of G protein-coupled receptors in yeast for higher functional production in eukaryotic expression hosts
por: Schütz, Marco, et al.
Publicado: (2016)

CRISPR-clear imaging of melanin-rich B16-derived solid tumors
por: Schubert, Rajib, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aut1qdgq24njtlgal4rnmgspao